BANK VONTOBEL/CALL/VERTEX PHARMACEUTICALS/500/0.1/20.09.24 | Real-time Boerse Frankfurt Warrants 01:53:14 22/05/2024 pm IST | ||
| 0.71 EUR | +12.70% |
|
| Current month | +133.33% | ||
| 1 month | +26.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 22/24/22 | 0.71 | +12.70% |
| 21/24/21 | 0.63 | -29.21% |
| 20/24/20 | 0.89 | +12.66% |
| 17/24/17 | 0.79 | +17.91% |
| 16/24/16 | 0.67 | +6.35% |
Real-time Boerse Frankfurt Warrants
Last update May 22, 2024 at 01:53 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Vontobel
|
| WKN | VM8JDT |
| ISIN | DE000VM8JDT6 |
| Date issued | 15/01/2024 |
| Strike | 500 $ |
| Maturity | 20/09/2024 (122 Days) |
| Parity | 10 : 1 |
| Emission price | 1.89 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.38 € |
|---|---|
| Lowest since issue | 0.24 € |
| Spread | 0.14 € |
| Spread % | 16.47% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
442
USD
Average target price
462.8
USD
Spread / Average Target
+4.71%
- Stock Market
- Warrants
- Warrant
